Onyx deal with Epttco

ONXX was up $2.563 (17 percent) to $17.50 on Wednesday on news that ONXX and Epttco (Abingdon, U.K.) will identify, evaluate and develop prodrugs that are converted by the enzyme nitroreductase into cytotoxins. ONXX will apply its Armed Therapeutic Virus ( ATV) technology to target the prodrug to cancer cells. ONXX has the right to obtain an exclusive global license to prodrugs resulting from the collaboration, and will gain access to the gene encoding nitroreductase. ...